- Home
- AUPH vs REAL Comparison
AUPH vs REAL Comparison
Compare AUPH & REAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AUPH | REAL |
|---|---|---|
| Founded | 1993 | 2011 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 2014 | 2019 |
Fundamental Metrics
Financial Performance| Metric | AUPH | REAL |
|---|---|---|
| Price | $16.15 | $12.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $17.25 | $17.00 |
| AVG Volume (30 Days) | 997.7K | ★ 2.7M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5075.00 | 43.55 |
| EPS | ★ 2.07 | N/A |
| Revenue | $283,055,000.00 | ★ $692,845,000.00 |
| Revenue This Year | $17.54 | $14.30 |
| Revenue Next Year | $15.74 | $10.15 |
| P/E Ratio | $7.89 | ★ N/A |
| Revenue Growth | ★ 20.38 | 15.38 |
| 52 Week Low | $7.29 | $4.71 |
| 52 Week High | $16.54 | $17.39 |
Technical Indicators
Market Signals| Indicator | AUPH | REAL |
|---|---|---|
| Relative Strength Index (RSI) | 60.05 | 66.41 |
| Support Level | $14.56 | $10.52 |
| Resistance Level | $16.32 | $12.84 |
| Average True Range (ATR) | 0.44 | 0.62 |
| MACD | 0.02 | 0.36 |
| Stochastic Oscillator | 44.15 | 86.30 |
Price Performance
Historical ComparisonAbout AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About REAL The RealReal Inc.
The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.